Jake Bauer - 13 Feb 2024 Form 4/A Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
13 Feb 2024
Net transactions value
$0
Form type
4/A
Filing time
20 Feb 2024, 19:26:11 UTC
Date Of Original Report
15 Feb 2024
Previous filing
06 Apr 2023
Next filing
10 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +23,364 $0.000000 23,364 13 Feb 2024 Common Stock 23,364 $14.85 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant.
F2 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date.